This session will explore some of the hottest new developments in the area of targeted cancer therapy; up-and-coming first- and/or best-in class compounds currently in clinical trials that hold promise to augment the limited number of currently marketed targeted therapies and extend survival and quality of life for cancer patients.

• Educate audience on a variety of novel inhibitors in development with both best-in-class and first-in-class potential for treating cancer and discuss what differentiates these drug candidates
• Generate discussion on currently marketed targeted cancer therapeutics — their benefits and limitations
• Elaborate on the concept of "targeted" versus "personalized" therapy, and what this means to each panelist with respect to the application and commercialization of the featured product candidates